BiotechTube

TNX-102 SL + Placebo

Phase 2Withdrawn
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

PTSD

Conditions

PTSD

Trial Timeline

Oct 14, 2022 → Nov 8, 2022

NCT ID
NCT05372887

About TNX-102 SL + Placebo

TNX-102 SL + Placebo is a phase 2 stage product being developed by Tonix Pharmaceuticals for PTSD. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05372887. Target conditions include PTSD.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT05372887Phase 2Withdrawn
NCT02277704Phase 2Completed

Competing Products

11 competing products in PTSD

See all competitors
ProductCompanyStageHype Score
SYN117 (nepicastat) + Placebo comparatorJohnson & JohnsonPhase 2
52
Quetiapine + PlaceboJohnson & JohnsonApproved
85
Lu AG06466 + PlaceboLundbeckPhase 1
30
Mifepristone 1200 mg daily + PlaceboCorcept TherapeuticsPhase 2
47
TNX-102 SLTonix PharmaceuticalsPhase 2
44
TNX-102 SL 5.6 mgTonix PharmaceuticalsPhase 3
69
TNX-102 SL + PlaceboTonix PharmaceuticalsPhase 2
44
TNX-102 SL + Placebo SL TabletTonix PharmaceuticalsPhase 3
69
TNX-102 SL + Placebo SL TabletsTonix PharmaceuticalsPhase 3
69
TNX-102 SLTonix PharmaceuticalsPhase 3
69
Ganaxolone + PlaceboBrain BiotechPhase 2
44

Other Products from Tonix Pharmaceuticals

TNX-102 SLPhase 3
69
TNX-102 SL 5.6 mgPhase 3
69
TNX-102 SL Tablet, 2.8 mg + Placebo SL TabletPhase 3
69
TNX-102 SL Tablet, 2.8mg + Placebo SL TabletPhase 3
69
TNX-102 SL + Placebo SL TabletPhase 3
69